COVID-19: Action collective

Déclaration officielle des fabricants mondiaux de médicaments génériques contre la COVID-19

En novembre 2020, 18 fabricants de médicaments génériques, représentant la plupart des acteurs du secteur, se sont réunis pour lancer une action collective, par l’entremise du Medicines Patent Pool (MPP), dans le but d’accélérer l’accès à des centaines de millions de doses de nouveaux traitements contre la COVID-19 dans les pays à revenu faible et intermédiaire. Les fabricants, désormais au nombre de 24, appellent les autres acteurs du secteur des médicaments génériques à les rejoindre en signant la Déclaration commune pour travailler ensemble, afin de mettre un terme à cette pandémie.

Nous sommes un collectif international d’acteurs de premier plan du domaine pharmaceutique qui produisons, fournissons et distribuons des traitements à des millions de personnes, pour la plupart dans les pays à revenu faible et intermédiaire. Notre signature est la preuve de notre engagement commun à apporter notre soutien à la lutte contre la COVID-19 et à travailler ensemble, en mettant nos capacités au service du développement et de la distribution à ceux qui en ont besoin de traitements contre la COVID-19. Et ce, qu’il s’agisse de médicaments repositionnés ou nouveaux, de petites molécules ou de produits biologiques.

Nous, signataires de la Déclaration commune, partageons notre engagement à lutter contre la COVID-19 et notre souhait de travailler avec le Medicines Patent Pool, organisation soutenue par les Nations Unies, pour que personne ne soit laissé sur le bord du chemin. Le modèle du MPP, qui a fait ses preuves et qui se caractérise par la transparence et la non-exclusivité, est la référence en matière de licences volontaires dans le domaine de la santé publique.

Accéder au communiqué de presse

La tâche est colossale, la demande globale. Chaque nouvel acteur, qu’il soit fabricant, fournisseur ou distributeur de génériques, permet au collectif de devenir plus fort. Pour rejoindre l’action collective et proposer vos capacités de production et/ou d’approvisionnement, cliquez sur « Rejoindre l’action collective » ci-dessous.

REJOINDRE L’ACTION COLLECTIVE

Pour montrer votre soutien aux efforts visant à ne laisser sur le bord du chemin aucun pays à revenu faible ou intermédiaire lorsque des traitements contre la COVID-19 seront disponibles, cliquez sur « Soutenir l’action collective » ci-dessous.

SOUTENIR L’ACTION COLLECTIVE

Remarque : le fait de rejoindre l’action collective ou de lui apporter votre soutien n’entraîne aucune obligation juridique ; il témoigne de votre intention et de votre soutien en faveur de l’accélération de l’accès au traitement pour ceux qui en ont besoin partout dans le monde, grâce au mécanisme d’octroi de licences volontaires du MPP.


Signataires :

“Working with MPP over the years has enabled Adcock Ingram to provide access to live saving medication to those in need in South Africa and its surrounds.”

 

“Associating with MPP has put us at the forefront of improving the accessibility and affordability of HIV medication. Our values and vision are closely aligned and they have continuously inspired us to do more for this cause.” – Arene Life Sciences

 

“We are committed to the cause of providing increased access to affordable high quality life saving medicines in low- and middle-income countries in several therapy areas including HIV. We have worked successfully with MPP over the years to this effect and will continue our fight through these valuable partnerships.” – Aurobindo

 

“MPP is committed to fighting health disparity through its unique strategy and we are proud to be a part of this network with the common goal of ensuring access to medicines for all.” – Beximco

 

“The very foundation of Cadila Pharmaceuticals is synonymous with quality and affordability of life-saving medicines. Our association with the MPP further strengthens our resolve to extend high-quality novel drugs to the last mile. Our expertise spans all major therapy areas and first-in-the-world innovations. Our immunomodulatory drug Sepsivac, used in gram negative sepsis, has been found to help in boosting innate immune response and has shown promising results in management of COVID 19 and also in increasing resistance against the development of COVID-19.”

 

Medicines Patent Pool has led
Paths of pharmaceutical products into
People’s lives.” – Celltrion

 

“Our endeavour to ensure equitable access to quality and affordable healthcare is entrenched in our humanitarian purpose of ‘Caring for Life’ that has driven our efforts in India and globally over the past 85 years. Our partnership with MPP has helped us in providing access to life-saving drugs for HIV and other therapies.” – Cipla

 

“The capacity and capability of global leading generics pharmaceutical manufacturers have been better utilized with MPP’s coordination to make the life-saving HIV and hepatitis C medicines available and affordable in LMICs. We Desano feel proud to be part of this.”

 

“MPP make life-saving medicines in low- and middle-income countries affordable, we feel great honour to be a member of the team, contributing our capacity and delivery.” – Jiangxi Dongbang Pharmaceutical

 

“We believe that accelerating access to good health requires – developing medicines where affordable alternatives don’t exist, working with all stakeholders in the healthcare systems and ensuring adequate availability of medicines. Aligned with our belief, ‘Good Health Can’t Wait’, we are committed to addressing unmet patient needs along with MPP.” – Dr. Reddy’s

 

“We are privileged to have partnered with MPP for the past decade which has led to creating a larger access to life-saving medicines across the globe; not only with HIV but for other therapies as well.” – Hetero

 

“Our company mission is contributing to the healthcare by supporting the improvement of medicine availability and affordability. It is great to work with MPP and Licensors to meet the urgent need of patients by providing more affordable medicines.” – Langhua Pharma

 

“MPP is spearheading an initiative that is so imperative for the developing countries around the world to have access to affordable, lifesaving medicines. We acknowledge the sincere efforts of Medicines Patent Pool to work alongside generic manufacturers to accelerate the development of affordable medications to LMICs.” – Lupin

 

“Access is at the core of all work undertaken by the team at MPP. This has helped in close cooperation between pharma and generics and has ensured that newer and safer medicines reach people across LMICs.” – Macleods

 

“We at Mangalam Drugs & Organics Ltd. take great pride in being associated with MPP that is striving relentlessly to provide rapid access to effective healthcare across the globe. Having partnered with this organisation has enabled us to envision beyond the ordinary. We look forward to continued alliance with them and to be able to build on each other’s strengths for sustainable benefits to those who have limited reach.”

 

“At Micro Labs we duly appreciate the initiative taken by the team at MPP. MPP’s efforts rightly opportune generic players to leverage their capabilities in reaching out to more patient population with quality and affordable medicines.”

 

“We believe the collaboration with MPP on expanding treatment access to affordable Hepatitis drugs has made a huge impact in many countries. It has been particularly satisfying to be part of the solution to tackle Hepatitis pandemic.” – Natco

 

“Our Stridian organizational values of Integrity, Collaboration and Efficiency resonate very well with those of the Medicines Patent Pool. Over the years, our partnership has promoted inclusivity, and worked towards making life-saving drugs affordable and accessible to large parts of the lower and middle income countries, thereby making a significant difference to public health.” – Strides Pharma

 

“The partnership with MPP & its licensing model has enabled supply of critical life-saving medicines to patients in low- & middle-income countries around the world.” – Sun Pharma

 

“Our association with MPP has strengthened our resolve in combating the scourge of hepatitis C. The inclusion of Daclatasvir to our anti-hep C portfolio has helped us extend Daclatasvir as a highly affordable treatment option to thousands of patients, suffering from hepatitis C, thereby improving both, their access to treatment and clinical outcomes.” – Zydus Cadila


Communiqué de presse

Pour plus d’informations, contactez :

Gelise McCullough
Cheffe en charge de la communications | Medicines Patent Pool
+41 79 685 64 36
gmccullough@medicinespatentpool.org

MPP Logo

Abonnez-vous à notre newsletter

Créé et financé par

Unitaid Logo

Autres financements

Ce site web utilise des cookies pour vous assurer une expérience utilisateur optimale. En savoir plus